Patent assignee · US · COMPANY

Cylene Pharmaceuticals, Inc.

21Patents
12Active
21Granted
40Portfolio score

Filing activity: May 20, 2002 → May 20, 2010 · 12 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US7141565B1 Substituted quinobenzoxazine analogs Chemistry; Metallurgy 22 Expired
US7956064B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators Chemistry; Metallurgy 20 Active
US7928100B2 Quinolone analogs and methods related thereto Chemistry; Metallurgy 17 Active
US7354916B2 Substituted quinobenzoxazine analogs Chemistry; Metallurgy 13 Expired
US7381720B2 Substituted quinobenzoxazine analogs Chemistry; Metallurgy 13 Expired
US7326702B2 Substituted quinobenzoxazine analogs Chemistry; Metallurgy 12 Expired
US7652134B2 Methods for converting quinolone esters into quinolone amides Chemistry; Metallurgy 11 Active
US7507727B2 Substituted quinobenzoxazine analogs and methods of using thereof Human Necessities 11 Expired
US7402579B2 Quinobenzoxazine analogs and compositions Human Necessities 11 Active
US7816406B2 Quinolone analogs Chemistry; Metallurgy 11 Active
US7612063B2 Substituted quinobenzoxazine analogs Chemistry; Metallurgy 11 Active
US8168651B2 Protein kinase modulators Chemistry; Metallurgy 9 Active
US7816524B2 Methods of preparing quinolone analogs Chemistry; Metallurgy 8 Active
US7834180B2 Methods of preparing quinolone analogs Chemistry; Metallurgy 3 Active
US8367681B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors Human Necessities 3 Active
US6933396B2 Process to prepare psorospermin Chemistry; Metallurgy 1 Expired
US7244760B2 Methods for preparation and use of psorospermin analogs Human Necessities 1 Expired
US7163948B2 Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs Human Necessities 1 Expired
US7001588B2 Expanded porphyrin compositions for tumor inhibition Chemistry; Metallurgy 0 Expired
US8124649B2 Oxindole compounds Chemistry; Metallurgy 0 Active
US7910600B2 Therapeutic kinase modulators Physics 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.